UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39655 GALECTO, INC. WASHINGTON, DC 20549 FORM 10-Q (Mark One) | | Trading | | | --- | --- | --- | | Title of each class | Symbol(s) | Name o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39655 GALECTO, INC. Ole Maaloes Vej 3 DK-2200 Copenhagen N 75 State Street, Suite 100 Registrant' ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 c FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC. Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39655 GALECTO, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 37-19 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39655 GALECTO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 37-1957007 (St ...

资金状况 - Galecto在2020年下半年筹集了约1.6亿美元，截止到2021年3月31日的现金余额为1.49亿美元，预计资金可持续到2024年[3] 临床试验与研发进展 - GB0139在特发性肺纤维化（IPF）中的临床试验正在进行中，预计2022年将完成入组[4] - GB2064是针对骨髓纤维化的口服LOXL2抑制剂，市场潜力巨大，Incyte的Jakafi在2020年和2019年的销售额分别为19亿美元和17亿美元[18] - GB0139的Phase 2a研究显示，生物标志物的变化被EMA视为在IPF患者中具有临床相关性，并为孤儿药物认定（ODD）提供了依据[11] - GALACTIC-1 Phase 2b研究的主要结果是52周内FVC（用力肺活量）下降的年化率，预计将对未使用pirfenidone或nintedanib的患者产生影响[12] - GB0139的3mg剂量组与安慰剂组的安全性数据初步显示出良好的安全性[13] - GB0139的吸入治疗通过通用吸入器直接将药物输送到目标组织，系统性暴露低[7] - GB0139在IPF患者中显示出剂量依赖性的药代动力学特征，且仅出现轻微的不良事件[10] - GB0139在肺部的浓度高，能够有效降低肺泡巨噬细胞中的galectin-3水平[9] - GB2064在体外显示出对LOXL2的强效抑制，完全抑制LOXL2活性[17] - MYLOX-1研究计划在未来几个月内开始首位患者给药，初步计划招募16名可评估患者，治疗时间为9个月[21] - GB2064的二期临床试验预计将在未来几个月启动，可能会同时显示疗效和靶向作用数据[22] - GB1211在多种动物模型中显示出抗纤维化和抗癌活性，已完成临床一期测试[23] - GB1211在非小细胞肺癌（NSCLC）中显示出高表达的galectin-3与对抗PD-1抗体的耐药性相关[27] - GB1211针对肝硬化的研究计划在2021年上半年进行，旨在展示药物对纤维化和肝功能的安全性和活性[32] - GB1211在健康志愿者的单剂量和多剂量研究中表现出良好的耐受性，最大剂量为400mg[42] - GB2064的IND于2020年10月获得批准，二期临床试验即将开始[22] - 预计GB1211将在2021年下半年启动与检查点抑制剂联合治疗的二期研究[29] - Galecto计划在未来几个月内启动三项二期临床研究，资金充足至2024年[36] - GB1211在10mg/kg剂量下，胶原蛋白减少，使用PSR（picosirius red staining）进行测量[49] - GB1211在实验中以10mg/kg剂量进行，采用每周两次的CCl4注射，持续8周[49] 市场需求与竞争 - 目前尚无批准的抗纤维化产品，市场对抗纤维化药物的需求迫切[49]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39655 GALECTO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 37-1957007 (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC. (Exact name of Registrant as specified in its Charter) | Delaware | 37-1957007 | | --- | --- | | (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39655 GALECTO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 37-195700 ...